Table 2.
Response Category | Patients with HCC Treated with Lenvatinib (n = 177) |
---|---|
CR | 6 (3%) |
PR | 57 (32%) |
SD | 72 (41%) |
PD | 42 (24%) |
ORR | 63 (38%) |
DCR | 135 (76%) |
Data are expressed as frequency (percentage). Abbreviations: HCC, hepatocellular carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.